In a report issued on February 24, Arun Jayaram from J.P. Morgan maintained a Buy rating on Diamondback (FANG – Research Report), with a price target of $153.00. The company’s shares closed last Friday at $137.80, close to its 52-week high of $142.09.
According to TipRanks.com, Jayaram is a 4-star analyst with an average return of 10.3% and a 55.0% success rate. Jayaram covers the Utilities sector, focusing on stocks such as Continental Resources, Antero Resources, and Pioneer Natural.
Diamondback has an analyst consensus of Strong Buy, with a price target consensus of $147.89, a 10.0% upside from current levels. In a report issued on February 23, Evercore ISI also maintained a Buy rating on the stock with a $130.00 price target.
Based on Diamondback’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.02 billion and net profit of $1 billion. In comparison, last year the company earned revenue of $767 million and had a GAAP net loss of $739 million.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FANG in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Diamondback Energy, Inc. is an independent oil and natural gas company, which engages in the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves. It operates through the Upstream and Midstream Services segments. The Upstream segment focuses on the Permian Basin operations in West Texas. The Midstream Services segment involves in the Midland and Delaware Basins. The company was founded in December 2007 and is headquartered in Midland, TX.
Read More on FANG:
- Krispy Kreme (DNUT) Gets a Buy Rating from J.P. Morgan
- J.P. Morgan Keeps a Buy Rating on Healthpeak Properties (PEAK)
- SITE Centers (SITC) Receives a Hold from J.P. Morgan
- J.P. Morgan Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)
- Analysts Have Conflicting Sentiments on These Materials Companies: Anglo American (OtherAAUKF) and Elanco Animal Health (ELAN)